Barbara White Acquires 1,389 Shares of Corbus Pharmaceuticals Holdings Inc (CRBP) Stock

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) insider Barbara White bought 1,389 shares of the stock in a transaction that occurred on Friday, May 17th. The stock was acquired at an average cost of $7.20 per share, for a total transaction of $10,000.80. Following the purchase, the insider now owns 185,548 shares of the company’s stock, valued at $1,335,945.60. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Barbara White also recently made the following trade(s):

  • On Thursday, March 14th, Barbara White bought 4,638 shares of Corbus Pharmaceuticals stock. The stock was acquired at an average cost of $6.47 per share, for a total transaction of $30,007.86.

Shares of CRBP stock traded down $0.04 during trading hours on Thursday, reaching $7.27. 17,950 shares of the company were exchanged, compared to its average volume of 982,092. Corbus Pharmaceuticals Holdings Inc has a fifty-two week low of $4.50 and a fifty-two week high of $9.11. The firm has a market capitalization of $471.20 million, a price-to-earnings ratio of -7.45 and a beta of 2.12. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.17.

Corbus Pharmaceuticals (NASDAQ:CRBP) last announced its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.02 by ($0.45). Corbus Pharmaceuticals had a negative return on equity of 166.99% and a negative net margin of 1,219.36%. The company had revenue of $1.89 million for the quarter, compared to analyst estimates of $20.97 million. On average, equities research analysts forecast that Corbus Pharmaceuticals Holdings Inc will post -1.2 earnings per share for the current fiscal year.

Hedge funds have recently made changes to their positions in the company. Alps Advisors Inc. lifted its position in shares of Corbus Pharmaceuticals by 30.7% during the fourth quarter. Alps Advisors Inc. now owns 132,272 shares of the biopharmaceutical company’s stock worth $772,000 after purchasing an additional 31,040 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Corbus Pharmaceuticals by 0.5% during the third quarter. Vanguard Group Inc. now owns 2,390,014 shares of the biopharmaceutical company’s stock worth $18,045,000 after purchasing an additional 11,609 shares in the last quarter. IFP Advisors Inc lifted its position in shares of Corbus Pharmaceuticals by 6.8% during the fourth quarter. IFP Advisors Inc now owns 1,608,569 shares of the biopharmaceutical company’s stock worth $9,458,000 after purchasing an additional 102,323 shares in the last quarter. D.A. Davidson & CO. lifted its position in shares of Corbus Pharmaceuticals by 76.5% during the fourth quarter. D.A. Davidson & CO. now owns 36,460 shares of the biopharmaceutical company’s stock worth $213,000 after purchasing an additional 15,800 shares in the last quarter. Finally, Vanguard Group Inc lifted its position in shares of Corbus Pharmaceuticals by 0.5% during the third quarter. Vanguard Group Inc now owns 2,390,014 shares of the biopharmaceutical company’s stock worth $18,045,000 after purchasing an additional 11,609 shares in the last quarter. Institutional investors own 35.30% of the company’s stock.

CRBP has been the topic of a number of analyst reports. Oppenheimer initiated coverage on shares of Corbus Pharmaceuticals in a research note on Tuesday, March 19th. They issued an “outperform” rating and a $28.00 target price on the stock. ValuEngine lowered shares of Corbus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 24th. Zacks Investment Research lowered shares of Corbus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, April 16th. CIBC assumed coverage on shares of Corbus Pharmaceuticals in a research report on Wednesday, March 20th. They issued an “outperform” rating and a $28.00 price target on the stock. Finally, BidaskClub upgraded shares of Corbus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, April 25th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Corbus Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $23.59.

ILLEGAL ACTIVITY NOTICE: “Barbara White Acquires 1,389 Shares of Corbus Pharmaceuticals Holdings Inc (CRBP) Stock” was originally published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/05/23/barbara-white-acquires-1389-shares-of-corbus-pharmaceuticals-holdings-inc-crbp-stock.html.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase 3 clinical trial for the treatment of systemic sclerosis and dermatomyositis, and in Phase 2 clinical trial to treat systemic lupus erythematosus and cystic fibrosis.

Further Reading: What is the Producer Price Index (PPI)?

Insider Buying and Selling by Quarter for Corbus Pharmaceuticals (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.